🇺🇸 FDA
Patent

US 11052057

Use of cysteamine and derivatives thereof to suppress tumor metastases

granted A61KA61K31/145A61K45/06

Quick answer

US patent 11052057 (Use of cysteamine and derivatives thereof to suppress tumor metastases) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/145, A61K45/06, A61K9/0053, A61K9/28